A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression
Authors:
- 12 June 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 146 (2) , 259-272
Abstract
Although there are effective HER2-targeted agents, novel combination strategies in HER2-overexpressing breast cancers are needed for patients whose tumors develop drug resistance. To develop new therapeutic strategy, we investigated the combinational effect of entinostat, an oral isoform-selective histone deacetylase type I inhibitor, and lapatinib, a HER2/EGFR dual tyrosine kinase inhibitor, in HER2+ breast cancer cells. We assessed the combinational synergistic effect and its mechanism by CellTiter Blue assay, flow cytometry, anchorage-independent growth, quantitative real-time PCR, small interfering RNA, Western blotting, and mammary fat pad xenograft mouse models. We found that compared with entinostat or lapatinib alone, the two drugs in combination synergistically inhibited proliferation (P < 0.001), reduced in vitro colony formation (P < 0.05), and resulted in significant in vivo tumor shrinkage or growth inhibition in two xenograft mouse models (BT474 and SUM190, P < 0.001). The synergistic anti-tumor activity of the entinostat/lapatinib combination was due to downregulation of phosphorylated Akt, which activated transcriptional activity of FOXO3, resulting in induction of Bim1 (a BH3 domain-containing pro-apoptotic protein). Furthermore, entinostat sensitized trastuzumab/lapatinib-resistance-HER2-overexpressing cells to the trastuzumab/lapatinib combination and enhanced the anti-proliferation effect compare with single or double combination treatment. This study provides evidence that entinostat has enhanced anti-tumor effect in combination with HER2-targeted reagent, lapatinib, and resulting in induction of apoptosis by FOXO3-mediated Bim1 expression. Our finding justifies for conducting a clinical trial of combinational treatment with entinostat, lapatinib, and trastuzumab in patients with HER2-overexpressing breast cancer resistant to trastuzumab-based treatment.Keywords
This publication has 52 references indexed in Scilit:
- FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive NeuroblastomaCancer Research, 2013
- FOXO3 Is Inhibited by Oncogenic PI3K/Akt Signaling but Can Be Reactivated by the NSAID Sulindac SulfideThe Journal of Clinical Endocrinology & Metabolism, 2011
- HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistanceCancer Letters, 2011
- PI3K pathway activation results in low efficacy of both trastuzumab and lapatinibBMC Cancer, 2011
- EGF-Receptor Targeting with Monoclonal Antibodies in Colorectal Carcinomas: Rationale for a Pharmacogenomic ApproachPharmacogenomics, 2007
- FOXO transcription factors at the interface between longevity and tumor suppressionOncogene, 2005
- FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell LinesJournal of Biological Chemistry, 2003
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 2003
- ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.2003
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.2001